9 Trametinib Interaction Guidelines

De Les Feux de l'Amour - Le site Wik'Y&R du projet Y&R.
Version du 1 décembre 2016 à 22:30 par Brianoffice0 (discuter | contributions)

(diff) ← Version précédente | Voir la version courante (diff) | Version suivante → (diff)

METHODS A search was conducted of standard electronic databases��such as MEDLINE, EMBASE, and the Cochrane Library��for randomized, FKBPL controlled trials comparing the effectiveness of PSC vs CLC of ileostomy wound. The MeSH terms published in the Medline library were used to ��hit�� upon the relevant trials. No restrictions for language, gender, sample size or place of study origin were entered for the search. Boolean operators (AND, OR, NOT) were appropriately utilized to narrow and widen the search results. The published titles from the resultant search were scrutinized closely and their suitability for potential inclusion into this study was assessed. The references from selected published articles were also checked as a further search tool, to find additional studies. For inclusion in the meta-analysis, a study had to meet the following criteria: (i) randomized, controlled trial; Trametinib cost (ii) comparison between PSC and CLC; (iii) evaluation of surgical site infection; (iv) main outcome measures reported preferably as an intention-to-treat (ITT) analysis; and (v) trials in surgical patients who had undergone ileostomy or jointly colostomy closure for any indication. Two reviewers, using a pre-defined meta-analysis form, extracted data from each study, which resulted in high and satisfactory inter-observer agreement. The extracted data contained information regarding the name of the authors, title of the study, journal in which the study was published, country and year of the study, treatment regimen, length of the therapy, testing sample size (with sex differentiation if applicable), the number of patients receiving each regimen and, within the group, the number of patients who succeeded and the number of patients who failed the allocated treatment, the patient compliance rate in each group, the number of patients reporting find more complications and the number of patients with absence of complications in each arm. The RevMan 5.2 software package [12, 13], provided by the Cochrane Collaboration, was used for the statistical analysis to achieve a combined outcome. The risk ratio (RR) with a 95% confidence interval (CI) was calculated for binary data, and the standardized mean difference (SMD) with a 95% CI was calculated for continuous variables. The random-effects model [14, 15] was used to calculate the combined outcomes of both binary and continuous variables. Heterogeneity was explored using the chi-squared (chi2) test��with significance set at P

Outils personnels